Table 3.
Smoking cessation outcomes by treatment condition and DRD2 Taq1A genotype.
| Percent abstinent (number of subjects/sample)
|
|||||
|---|---|---|---|---|---|
| Treatment condition | DRD2 Taq1A genotype | Assessment of abstinence | Study 1 (N=431)* | Study 2 (N=291) | Pooled data (N=722)* |
| Bupropion | A1/A1 or A1/A2 | End of treatment | 25.7 (26/101) | 44.4 (28/63) | 32.9 (54/164) |
| Placebo | 25.3 (20/79) | 25.8 (17/66) | 25.5 (37/145) | ||
| Bupropion | A2/A2 | 29.5 (38/129) | 45.2 (33/73) | 35.2 (71/202) | |
| Placebo | 12.1 (14/116) | 19.1 (17/89) | 15.1 (31/205) | ||
| Bupropion | A1/A1 or A1/A2 | 6 months | 20.8 (21/101) | 23.8 (15/63) | 22.0 (36/164) |
| Placebo | 12.7 (10/79) | 27.3 (18/66) | 19.3 (28/145) | ||
| Bupropion | A2/A2 | 20.9 (27/129) | 37.0 (27/73) | 26.7 (54/202) | |
| Placebo | 10.3 (12/116) | 14.6 (13/89) | 12.2 (25/205) | ||
| Bupropion | A1/A1 or A1/A2 | 12 months | 11.9 (12/101) | 17.5 (11/63) | 14.0 (23/164) |
| Placebo | 8.9 (7/79) | 18.2 (12/66) | 13.1 (19/145) | ||
| Bupropion | A2/A2 | 14.7 (19/129) | 19.2 (14/73) | 16.3 (33/202) | |
| Placebo | 8.6 (10/116) | 13.5 (12/89) | 10.7 (22/205) | ||
Note. Frequencies for participants at both study sites who reported continuous abstinence with biochemically verified 7-day point prevalence, grouped by treatment condition using intention-to-treat criteria and DRD2 Taq1A genotype.
a
Smoking outcomes data missing on 6 individuals in Study 1 (3 each for the A1/A1 or A1/A2 group, and for the A2/A2 group).